WO2011008985A3 - Conjugates comprising dna-binding agent for targeted delivery of therapeutic agents - Google Patents

Conjugates comprising dna-binding agent for targeted delivery of therapeutic agents Download PDF

Info

Publication number
WO2011008985A3
WO2011008985A3 PCT/US2010/042175 US2010042175W WO2011008985A3 WO 2011008985 A3 WO2011008985 A3 WO 2011008985A3 US 2010042175 W US2010042175 W US 2010042175W WO 2011008985 A3 WO2011008985 A3 WO 2011008985A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
dna
conjugates
derivatives
binding agent
Prior art date
Application number
PCT/US2010/042175
Other languages
French (fr)
Other versions
WO2011008985A2 (en
Inventor
Niren Murthy
Michael E. Davis
Dongin Kim
Madhuri Dasari
Sungmun Lee
Seungjun Lee
Jay Sy
Mark Goodman
Original Assignee
Georgia Tech Research Corporation
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corporation, Emory University filed Critical Georgia Tech Research Corporation
Publication of WO2011008985A2 publication Critical patent/WO2011008985A2/en
Publication of WO2011008985A3 publication Critical patent/WO2011008985A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Among other things, this disclosure provides for compounds having a targeting moiety linked to a therapeutic moiety and/or a diagnostic moiety; the synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and, methods for treating or diagnosing disorders. Some of the compounds include a linker which can be cleaved under physiological conditions, including linkers comprising an amide or disulfide bond. Examples of targeting moieties are derivatives of DNA binding agents, which may comprise derivatives of Hoechst 33258. Examples of therapeutic moieties are compounds useful for treating a cancer, which may comprise derivatives of nucleotides and nucleosides such as gemcitabine. This abstract is intended to be used as a scanning tool for the purposes of searching in the particular art and is not intended to limiting of the present disclosure.
PCT/US2010/042175 2009-07-15 2010-07-15 Methods and compositions for improved delivery of therapeutic and diagnostic agents WO2011008985A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22564909P 2009-07-15 2009-07-15
US61/225,649 2009-07-15

Publications (2)

Publication Number Publication Date
WO2011008985A2 WO2011008985A2 (en) 2011-01-20
WO2011008985A3 true WO2011008985A3 (en) 2011-04-14

Family

ID=43332508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042175 WO2011008985A2 (en) 2009-07-15 2010-07-15 Methods and compositions for improved delivery of therapeutic and diagnostic agents

Country Status (1)

Country Link
WO (1) WO2011008985A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102432654A (en) * 2011-09-26 2012-05-02 宋云龙 Gemcitabine amide derivates, and preparation method and application thereof
CN105849087A (en) 2013-12-27 2016-08-10 诺华丝国际股份有限公司 Ethoxylated surfactants
MX2020004054A (en) * 2014-06-25 2021-11-30 NuCana plc Formulation comprising a gemcitabine-prodrug.
WO2015200187A1 (en) * 2014-06-27 2015-12-30 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
WO2023242766A1 (en) * 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037499A2 (en) * 2006-09-29 2008-04-03 Leukocare Ag Method for the detection of an activation of the immune system or the extent of cell death

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037499A2 (en) * 2006-09-29 2008-04-03 Leukocare Ag Method for the detection of an activation of the immune system or the extent of cell death

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARYA D P ET AL: "Reaching into the Major Groove of B-DNA: Synthesis and Nucleic Acid Binding of a Neomycin - Hoechst 33258 Conjugate", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 125, 19 September 2003 (2003-09-19), pages 12398 - 12399, XP008091374, ISSN: 0002-7863, DOI: DOI:10.1021/JA036742K *
CHI-HONG B CHEN ET AL: "NUCLEASE ACTIVITY OF 1,10-PHENANTHROLINE-COPPER. NEW CONJUGATES WITH LOW MOLECULAR WEIGHT TARGETING LIGANDS", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 4, no. 1, 1 January 1993 (1993-01-01), pages 69 - 77, XP000336593, ISSN: 1043-1802, DOI: DOI:10.1021/BC00019A010 *
FRAU S ET AL: "NUCLEASE ACTIVITY AND BINDING CHARACTERISTICS OF A CATIONIC MANGANESE PORPHYRIN - BIS(BENZIMIDAZOLE) DYE (HOECHST 33258) CONJUGATE", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 8, 1 March 1997 (1997-03-01), pages 222 - 231, XP000198879, ISSN: 1043-1802, DOI: DOI:10.1021/BC970007E *
GARANGER E ET AL: "A DNA-binding Gd chelate for the detection of cell death by MRI", CHEMICAL COMMUNICATIONS 2009 ROYAL SOCIETY OF CHEMISTRY GBR LNKD- DOI:10.1039/B907375B, no. 29, 12 June 2009 (2009-06-12), pages 4444 - 4446, XP002615322, ISSN: 1359-7345 *
GRAVATT ET AL: "DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol (Hoechst 33258)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 37, no. 25, 1 January 1994 (1994-01-01), pages 4338 - 4345, XP002331450, ISSN: 0022-2623, DOI: DOI:10.1021/JM00051A010 *
WIEDERHOLT KRISTIN ET AL: "DNA-Tethered Hoechst Groove-Binding Agents: Duplex Stabilization and Fluorescence Characteristics", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 118, no. 30, 1 January 1996 (1996-01-01), pages 7055 - 7062, XP002111428, ISSN: 0002-7863, DOI: DOI:10.1021/JA960948M *

Also Published As

Publication number Publication date
WO2011008985A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2011008985A3 (en) Conjugates comprising dna-binding agent for targeted delivery of therapeutic agents
US10485881B2 (en) Nanoparticle drug conjugates
CA2653941C (en) Substituted amino purine derivatives and uses thereof
KR101413955B1 (en) Aziridinyl-epothilone compounds
MX2010003927A (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors.
WO2008137758A3 (en) Amino acid lipids and uses thereof
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
JO2744B1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2012001399A (en) Prodrugs comprising an insulin linker conjugate.
WO2009019534A3 (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EA200800564A1 (en) DERIVATIVES OF XANTHINE AS SELECTIVE AGONISTS NM74A
WO2013158644A3 (en) Targeted therapeutics
BR122019017036B8 (en) tetrazole-substituted arylamide compounds, uses of said compounds and pharmaceutical composition
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
HK1092708A1 (en) Polyacetal drug conjugates as release system
CY1110990T1 (en) ADENOSINE PRODUCTS AS A2A RECEPTOR RACERS
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2008012470A3 (en) Substituted imidazolone derivatives, preparation and uses
TW200637863A (en) Organic compounds
HK1123728A1 (en) Immuno-rna-constructs
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
WO2011053901A3 (en) Magnetic nanostructures as theranostic agents
WO2015066053A3 (en) Targeted therapeutics
WO2011029008A3 (en) Synbodies to akt1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10735137

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10735137

Country of ref document: EP

Kind code of ref document: A2